Anavex Life Sciences (AVXL) said Tuesday it filed a marketing authorization application with the European Medicines Agency for blarcamesine to treat Alzheimer's disease.
Anavex said that blarcamesine, which is administered orally once a day, showed "clinically meaningful improvement over 48 weeks with primary endpoint ADAS-Cog13 score being larger than 2 points."
"This suggests superior numerical clinical efficacy compared to approved therapies while also slowing neurodegeneration in early [Alzheimer's disease] patients," the company said.
This is the first marketing authorization filing for the drug, Anavex said.
Anavex shares were more than 13% higher in premarket trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.